Drugs / recombinant fowlpox-tyrosinase vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00054535 | Jan 2003 → Sep 2004 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-tyrosinase vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00054535 ↗ |
| Modality | Vaccine | “recombinant fowlpox-tyrosinase vaccine” NCT00054535 ↗ |
| Route | Intramuscular | “fowlpox-tyrosinase vaccine IM on days 15 and 29” NCT00054535 ↗ |